



INVESTOR IN PEOPLE

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 24 NOV 2003

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., p.l.c. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

12 November 2003

**CERTIFIED COPY OF
PRIORITY DOCUMENT BEST AVAILABLE COPY**

Patent Act 1977
(Rule 16)




1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ



1. Your reference

SCG/CP6107775

2. Patent application number

(The Patent Office will fill in this part)

0229750.5

20 DEC 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Patents ADP number (if you know it)

ANGEL TECHNOLOGY LIMITED
THE WELL HOUSE
WISHANGER
CHURT
FARHNAM
SURREY GU10 2QJ
UNITED KINGDOM

20 DEC 2002 E772743-7 000060

P01/7700 0.00-0229750.5

If the applicant is a corporate body, give the country/state of its incorporation

GB

08532095001

4. Title of the invention

CHEESE ALTERNATIVE PRODUCT AND PROCESS FOR
PREPARING A CHEESE ALTERNATIVE PRODUCT

5. Name of your agent (if you have one)

MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

YORK HOUSE
23 KINGSWAY
LONDON
WC2B 6HP

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request?

(Answer "Yes" if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

YES

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 8

Claim(s) 2

Abstract 0

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77) 0

Any other documents (Please specify) 0

11. I/We request the grant of a patent on the basis of this application.

Signature

Stephen Gill

Date

19 December 2002

12. Name and daytime telephone number of person to contact in the United Kingdom
- | | |
|--------------|--------------|
| STEPHEN GILL | 01223 420383 |
|--------------|--------------|

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

CHEESE ALTERNATIVE PRODUCT AND PROCESS FOR PREPARING A
CHEESE ALTERNATIVE PRODUCT

The present invention relates to a cheese alternative product and a process for preparing a cheese alternative product.

It is well established that ingestion of saturated fat can increase blood plasma total cholesterol concentration, and that this concentration is correlated with the extent of atherosclerosis and the incidence of coronary heart disease.

There has, therefore, been significant interest among consumers in food products which lower blood cholesterol levels. To this end, WO 96/38047 describes "healthy" spreads and a dressing formed from oryzanol-enriched refined sunflower oil, oryzanol being found to lower blood cholesterol levels. WO 96/38047 also suggests that phytosterols, tocopherols and tocotrienols can be used to lower cholesterol levels.

The present invention is at least partly based on the realisation that the benefits of blood cholesterol lowering compounds can also be obtained in foodstuffs, such as cheese, that usually are so high in dairy origin fats (which in turn are high in saturated fats) as to be considered "unhealthy" for consumers at risk from high cholesterol levels.

As used herein, by "blood cholesterol lowering agent" we mean phytosterol, oryzanol, tocopherol, tocotrienol, polyphenol or a mixture of any two or more thereof.

In general terms the present invention provides a cheese alternative product containing a blood cholesterol lowering

agent in an amount sufficient to have a blood cholesterol level lowering effect. That is, the blood cholesterol lowering agent should be present in an amount sufficient to partly or wholly counteract the blood cholesterol

5 increasing effect of any saturated fat in the product.

However, preferably the blood cholesterol lowering agent also has a general effect such that ingestion of the product decreases the blood plasma total cholesterol concentration.

10 Oryzanol consist of a mixture of ferulic acid esters of unsaturated triterpene alcohols and is also referred to as gamma-oryzanol. Only the term oryzanol is used herein.

Within the group of tocopherols and tocotrienols one can distinguish alpha, beta, gamma and delta tocopherols and
15 tocotrienols depending on the number and position of the methyl substituents on the chromane ring of the molecule.

The terms tocopherol and tocotrienol are used herein to cover this whole family of molecules. For a further description and schematic drawings of oryzanol, tocopherol
20 and tocotrienol according to the present invention, reference is made to "Separation of Vitamin E and gamma-Oryzanols from Rice Bran by Normal- phase Chromatography", M. Diack and M. Saska, *JAOCS* Vol.71, no.11, pp. 1211.

Phytosterols, also known as plant sterols or vegetable
25 sterols can be classified in three groups, 4-desmethylsterols, 4-monomethylsterols and 4,4'-dimethylsterols. In oils they mainly exist as free sterols and sterol esters of fatty acids, although sterol ~~glucosides and acylated sterol glucosides~~ are also present.

30 There are three major phytosterols namely beta-sitosterol, stigmasterol and campesterol. Schematic drawings of phytosterols according to the present invention are given

in "Influence of Processing on Sterols of Edible Vegetable Oils", S.P. Kochhar, *Prog. Lipid Res.* 22: pp. 161-188. The term phytosterol as used herein covers the whole group of free phytosterols, phytosterol fatty acid esters and (acylated) phytosterol glucosides.

Polyphenols (or phenolics) can be defined chemically as substances which possess an aromatic ring bearing one or more hydroxy substituents, including functional derivatives. Reference is made to "Phenolic Compounds in Food", Chi-Tang Ho; *Phenolic Compounds in Food and Their Effects on Health II*, Am. Chemical Soc., 1992. As used herein, the term polyphenol refers to all plant phenolic molecules derived from a plant source with an antioxidant activity and not covered by the terms oryzanol, tocotrienol and tocopherol, e.g. simple phenols and phenolic acids, hydroxycinnamic acid derivatives (e.g. coumaric and ferulic acid) and flavonoids.

In a first aspect, the present invention provides a cheese alternative product prepared from filled milk formed from dairy origin skimmed milk and vegetable oil, wherein the vegetable oil contains blood cholesterol lowering agent in an amount such that in the product the blood cholesterol lowering agent has a blood cholesterol level lowering effect. As used herein, the term "filled milk" pertains to a water-continuous composition containing oil of a non-dairy origin, i.e. not derived from a milk product.

Advantageously, the vegetable oil not only introduces the blood cholesterol lowering agent into the product, but also displaces a significant amount of "unhealthy" dairy origin fat from the product (e.g. allows skimmed milk to be used in place of bovine fat milk).

Preferably the blood cholesterol lowering agent is phytosterol.

The vegetable oil may be rice bran oil, wheat germ oil, maize germ oil, oat oil, oat bran oil, sesame seed oil, soybean oil, sheanut oil, palm oil or a mixture of any two or more thereof. Preferably, the oil may be rice bran oil, wheat germ oil, maize germ oil, oat oil, oat bran oil, sesame seed oil, soybean oil, sheanut oil or a mixture of any two or more thereof, as these oils all contain significant amounts of naturally-occurring phytosterol. More preferably the vegetable oil is wheat germ oil and/or rice bran oil.

In one embodiment, the filled milk contains only the skimmed milk and the vegetable oil. The milk from which the cheese is formed is then an entirely "natural" product, which should increase the consumer acceptability of the product.

The cheese alternative product may contain at least 0.1 wt.% of blood cholesterol lowering agent, the weight percentage being based on the total weight of the cheese alternative product. We have found that relatively low amounts of blood cholesterol lowering agent in cheese products can be beneficial because the average daily intake of such products tends to be high. In contrast, spreads and similar products are generally consumed in smaller daily amounts, and so the amount of blood cholesterol lowering agent that is sometimes added to these products usually has to be higher.

However, in other embodiments the cheese alternative product contains at least 0.2, 0.5, 1 or 2 wt.% of blood cholesterol lowering agent.

Preferably the cheese alternative product contains at most 10 wt.% of blood cholesterol lowering agent, and more preferably at most 5 or 3 wt.%.

5 The product may be a cheese alternative to any of a wide variety of cheeses e.g. gouda, mozzarella, Roquefort, cheddar etc. However, preferably the product is a hard cheese alternative, such as a gouda or cheddar alternative.

10 A further aspect of the invention provides a process for preparing a cheese alternative product containing blood cholesterol lowering agent (which is preferably phytosterol) in an amount sufficient to have a blood cholesterol level lowering effect, the process comprising:

15 mixing vegetable oil with dairy origin skimmed milk to form filled milk, the vegetable oil containing blood cholesterol lowering agent,

forming curd and whey by adding a starter culture and/or a coagulant to the filled milk, and separating the whey from the curd.

20 The curd can then be processed in a number of easy to obtain different styles of cheese alternative product, e.g. cheddar-style, gouda-style etc.

Preferably, the mixing is performed by injecting the vegetable oil into the skimmed milk to atomise and disperse the vegetable oil.

25 Filled milks can be formed by mechanical agitation of skimmed milk and non-dairy origin oil, a purpose of the agitation being to reduce the oil droplet size and to form a stable oil in water emulsion. However, agitation can destroy or damage the milk proteins, such as casein,
30 essential for cheese production. We have found that

injection atomising the vegetable oil allows a fine and homogeneous dispersion of vegetable oil droplets to be produced in the skimmed milk without significant damage to the skimmed milk casein. Furthermore, the oil thus dispersed appears to have an improved stability, such that problems of oil "sweating" from cheese alternatives obtained by the process are reduced or avoided. Also the thermal melting behaviour of the cheese alternative can be substantially similar to that of the corresponding "conventional" cheese produced without addition of vegetable oil.

Another aspect of the invention provides a cheese alternative product obtained by the process of the previous aspect. For example, the process may be used to obtain a cheese alternative product of the first aspect of invention.

The invention is illustrated by means of the following example which relates to a cheddar alternative.

Example

Raw milk used to produce the cheese alternative product was stored at less than 6°C. The raw milk was preheated to 55°C and introduced into a centrifugal separator which separated the raw milk into 40 vol.% fat cream and 0.05 vol.% skimmed milk.

Refined wheat germ oil, which is naturally high in phytosterols, was heated to 45°C and then injected into the skimmed milk. The injection system comprised a 50 mm diameter tube along which the skimmed milk (now also at 45°C) was passed at a pressure of 1.5 bar and a flow rate of approximately 21,000 litres per hour. Four to six

injection nozzles of 0.7 mm diameter formed in the wall of the tube allowed the wheat germ oil to be radially injected into the skimmed milk stream at a pressure in the range 200-220 bar. The nozzle orifices were covered with brass gauze to prevent any debris blocking the nozzle exits.

With this system the oil was injected at between 700 to 1,000 litres per hour, which produced a filled milk having 4 vol.% total fat. The injection caused the oil to atomise and form a stable emulsion with a consistent and small oil globule size.

Next, the filled milk was held at 73°C for more than 20 seconds to pasteurise milk. The milk was cooled to 31°C and divided into 15000 kg batches to fill respective cheesemaking vats. 3 x 500 g of mesophilic dairy starter culture was added to each batch, which was then allowed to ripen for 45 minutes to acidify the cheesemilk and generate flavour in the finished product.

1.25 kg of microbial rennet was added to each batch and the cheesemilk agitated for 3 minutes. The milk was left to coagulate and to develop flavour for 55 minutes. The coagulum was then cut with vertical knives to produce solid curd and liquid whey. Whilst being stirred, steam was applied to the vat jacket to increase the temperature to between 37 and 39.5°C. Stirring continued for a further ten minutes at this temperature and the vat contents then emptied onto perforated cooling/cheddaring tables.

Liquid whey drained off through the perforations and the curd was further agitated and squeezed until a titratable acidity of 0.4 vol.% lactic acid in the whey was reached, whereupon the curd was milled to thumbnail size. Salt was added to the curd and the salted curd used to fill cloth

lined stainless steel moulds. These were pressed at 60-100 psi overnight to expel further moisture and obtain a regular block shape. Finally, each block was held at 8 to 12°C for 6 to 12 weeks to mature.

5 At the start of the cheesemaking process each vat contained:

14400 kg skimmed milk,
600 kg wheatgerm oil,
1.5 kg dairy culture, and
10 1.25 coagulant.

Proportionately, about 43 kg of salt was subsequently added.

From this about 1580 kg of finished cheese alternative product was obtained having good oil retention,
15 meltability, texture and flavour, containing:
total fat content = 32 to 36 wt.%,
moisture level = 34.5 to 38.5 wt.%, and
salt = 1.65 to 2.15 wt.%,
and having a pH in the range 5.15 to 5.45 pH.

CLAIMS

1. A cheese alternative product prepared from filled milk formed from dairy origin skimmed milk and vegetable oil, wherein

5 the vegetable oil contains blood cholesterol lowering agent in an amount such that in the product the blood cholesterol lowering agent has a blood cholesterol level lowering effect, and

10 the blood cholesterol lowering agent is phytosterol, oryzanol, tocopherol, tocotrienol, polyphenol or a mixture of any two or more thereof.

2. A cheese alternative product according to claim 1 containing at least 0.1 wt.% of blood cholesterol lowering agent.

15 3. A cheese alternative product according to claim 1 or 2 wherein the blood cholesterol lowering agent is phytosterol.

20 4. A process for preparing a cheese alternative product containing blood cholesterol lowering agent in an amount sufficient to have a blood cholesterol level lowering effect, the process comprising:

mixing vegetable oil with dairy origin skimmed milk to form filled milk, the vegetable oil containing blood cholesterol lowering agent,

25 forming curd and whey by adding a starter culture and/or a coagulant to the filled milk, and

separating the whey from the curd;

wherein the blood cholesterol lowering agent is phytosterol, oryzanol, tocopherol, tocotrienol, polyphenol
30 or a mixture of any two or more thereof.

5. A process according to claim 4, wherein the mixing is performed by injecting the vegetable oil into the skimmed milk to atomise and disperse the vegetable oil.

6. A process according to claim 4 or 6, wherein the blood
5 cholesterol lowering agent is phytosterol.

7. A cheese alternative product obtained by the process of any one of claims 4 to 6.

PCT Application
GB0304704



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/04704

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A23C19/093 A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A23C A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 088 195 A (VITAMINS INC) 25 October 1967 (1967-10-25) page 3, column 1, line 59 - column 2, line 73; examples 1,2	1-7
X	GB 2 255 489 A (ST IVEL LTD) 11 November 1992 (1992-11-11) page 1, paragraph 1-2 page 3, paragraph 1-2 page 4, paragraph 4 - page 5, paragraph 2 claims; examples B1-B6 page 6, paragraph 3	1,3,4,6, 7
X	GB 2 214 776 A (UNILEVER PLC) 13 September 1989 (1989-09-13) claims; example 1	1,3-7

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the International search

26 February 2004

Date of mailing of the International search report

11/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Baminger, U

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/04704

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 063 074 A (KAHN MARVIN L ET AL) 5 November 1991 (1991-11-05) claims; examples 1,5 -----	1,3,4,6, 7
Y	WO 96/38047 A (UNILEVER PLC ; UNILEVER NV (NL); LIEVENSE LOURUS CORNELIS (NL)) 5 December 1996 (1996-12-05) cited in the application page 11, line 4 - page 13, line 25 page 4, line 13 - page 6, line 10 page 7, line 7 - page 8, line 22 -----	1-7
Y	US 6 156 354 A (HAYES KENNETH C ET AL) 5 December 2000 (2000-12-05) column 28; table 2 -----	1-7
Y	WO 00/33669 A (DAHLSTEN CARL JOHAN ; ARLA FOU (SE); BURLING HANS (SE); STRINNING OLOF) 15 June 2000 (2000-06-15) example 11 -----	1-7
P,Y	WO 03/009708 A (NESTLE SA ; BERGER ALVIN (CH); LESER MARTIN (CH); GROUX MICHEL JOHN AR) 6 February 2003 (2003-02-06) page 20, paragraph 2; claims; example 1 page 15, paragraph 1 page 10, paragraph 3 page 8, paragraph 2 - page 9, paragraph 1 page 3, paragraph 3 -----	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/04704

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 1088195	A	25-10-1967	NONE	
GB 2255489	A	11-11-1992	IE 920086 A1	15-07-1992
GB 2214776	A	13-09-1989	AU 617684 B2	05-12-1991
			AU 2063788 A	16-02-1989
			BE 1002252 A3	06-11-1990
			EP 0304119 A2	22-02-1989
			FR 2619286 A1	17-02-1989
			JP 1067151 A	13-03-1989
			ZA 8805976 A	25-04-1990
US 5063074	A	05-11-1991	US 5175015 A	29-12-1992
WO 9638047	A	05-12-1996	AU 1347500 A	20-04-2000
			AU 1347600 A	20-04-2000
			AU 6003796 A	18-12-1996
			BR 9608914 A	02-03-1999
			CA 2222771 A1	05-12-1996
			CA 2362968 A1	05-12-1996
			DE 69606638 D1	16-03-2000
			DE 69606638 T2	20-07-2000
			DE 69629502 D1	18-09-2003
			DK 828434 T3	13-06-2000
			DK 962150 T3	08-12-2003
			WO 9638047 A1	05-12-1996
			EP 0828434 A1	18-03-1998
			EP 0960567 A2	01-12-1999
			EP 0962150 A2	08-12-1999
			ES 2142589 T3	16-04-2000
			JP 11506324 T	08-06-1999
			US 2003134028 A1	17-07-2003
			ZA 9604554 A	03-12-1997
			AU 1347200 A	06-04-2000
			AU 1347300 A	06-04-2000
			AU 1347400 A	06-04-2000
US 6156354	A	05-12-2000	AU 2970600 A	18-08-2000
			WO 0044237 A2	03-08-2000
			US 6503545 B1	07-01-2003
WO 0033669	A	15-06-2000	SE 513973 C2	04-12-2000
			AU 2017000 A	26-06-2000
			EP 1137344 A1	04-10-2001
			SE 9804253 A	09-06-2000
			SE 516677 C2	12-02-2002
			SE 9902167 A	09-06-2000
			WO 0033669 A1	15-06-2000
WO 03009708	A	06-02-2003	WO 03009708 A1	06-02-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.